Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer

The aim of this multi-institutional study was to identify predictors of residual high-grade (HG) disease at re-transurethral resection (reTUR) in a large cohort of primary T1 HG/Grade 3 (G3) bladder cancer patients. A total of 1155 patients with primary T1 HG/G3 bladder cancer from 13 academic institutions that underwent a reTUR within 6 weeks after first TUR were evaluated. Logistic regression analysis was performed to assess the association of predictive factors with residual HG at reTUR. Residual HG cancer was found in 288 (24.9%) of patients at reTUR. Patients presenting residual HG cancer were more likely to have carcinoma in situ (CIS) at first resection (p<0.001), multiple tumors (p=0.02), and tumor size larger than 3 cm (p=0.02). Residual HG disease at reTUR was associated with increased preoperative neutrophil-to-lymphocytes ratio (NLR) (p=0.006) and body mass index (BMI)>=25 kg/m. On multivariable analysis, independent predictors for HG residual disease at reTUR were tumor size >3cm (OR = 1.37; 95% CI: 1.02-1.84, p=0.03), concomitant CIS (OR 1.92; 95% CI: 1.32-2.78, p=0.001), being overweight (OR= 2.08; 95% CI: 1.44-3.01, p<0.001) and obesity (OR 2.48; 95% CI: 1.64-3.77, p<0.001). A reTUR in high grade T1 bladder cancer is mandatory as about 25% of patients, presents residual high grade disease. Independent predictors to identify patients at risk of residual high grade disease after a complete TUR include tumor size, presence of carcinoma in situ, and BMI >=25 kg/m.

Citing Articles

A multimodal deep-learning model based on multichannel CT radiomics for predicting pathological grade of bladder cancer.

Zhao T, He J, Zhang L, Li H, Duan Q Abdom Radiol (NY). 2024; .

PMID: 39690281 DOI: 10.1007/s00261-024-04748-0.

Current opinions regarding the clinical utility of en bloc resection in the treatment of non-muscle invasive bladder cancer-a review of the literature.

Gao W Discov Oncol. 2024; 15(1):574.

PMID: 39425810 PMC: 11490474. DOI: 10.1007/s12672-024-01452-9.

Impact of multi-parameter images obtained from dual-energy CT on radiomics to predict pathological grading of bladder urothelial carcinoma.

Wei W, Wang S, Hu M, Tong X, Fan Y, Zhang J Abdom Radiol (NY). 2024; 49(12):4324-4333.

PMID: 39134869 DOI: 10.1007/s00261-024-04516-0.

Do we need a re-TUR after en bloc resection of T1 stage bladder cancer?.

Levy S, Pericart S, Bajeot A, Fakhfakh S, Lesourd M, Soulie M World J Urol. 2024; 42(1):475.

PMID: 39115589 PMC: 11310258. DOI: 10.1007/s00345-024-05175-y.

Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer.

Ham W, Park J, Jang W, Kim J Ann Surg Oncol. 2023; 31(2):1384-1392.

PMID: 37884699 DOI: 10.1245/s10434-023-14449-5.

References

Divrik R, Sahin A . Re: Maurizio A. Brausi. Challenging the EAU guidelines regarding early repeat transurethral resection. Eur Urol Suppl 2011;10:e5-7. Eur Urol. 2012; 62(1):e21-2. DOI: 10.1016/j.eururo.2012.03.015. View

Naselli A, Hurle R, Paparella S, Buffi N, Lughezzani G, Lista G . Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2017; 4(4):558-567. DOI: 10.1016/j.euf.2016.12.011. View

Husillos Alonso A, Rodriguez Fernandez E, Herranz Amo F, Lopez Lopez E, Aragon Chamizo J, Ramirez Martinez D . The need for re-TUR of the bladder in non-muscle invasive bladder cancer: risk factors of tumor persistence in re-TUR specimens. Minerva Urol Nefrol. 2014; 66(4):233-40. View

Schwaibold H, Sivalingam S, May F, Hartung R . The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006; 97(6):1199-201. DOI: 10.1111/j.1464-410X.2006.06144.x. View

Kamiya N, Suzuki H, Suyama T, Kobayashi M, Fukasawa S, Sekita N . Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study. Int J Clin Oncol. 2016; 22(2):353-358. DOI: 10.1007/s10147-016-1048-z. View

Gacci M, Sebastianelli A, Salvi M, De Nunzio C, Tubaro A, Vignozzi L . Central obesity is predictive of persistent storage lower urinary tract symptoms (LUTS) after surgery for benign prostatic enlargement: results of a multicentre prospective study. BJU Int. 2015; 116(2):271-7. DOI: 10.1111/bju.13038. View

Cao M, Yang G, Pan J, Sun J, Chen Q, Chen Y . Repeated transurethral resection for non-muscle invasive bladder cancer. Int J Clin Exp Med. 2015; 8(1):1416-9. PMC: 4358603. View

Vianello A, Costantini E, Del Zingaro M, Bini V, Herr H, Porena M . Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis. J Endourol. 2011; 25(11):1703-12. DOI: 10.1089/end.2011.0081. View

Gill T, Das R, Basu S, Dey R, Mitra S . Predictive factors for residual tumor and tumor upstaging on relook transurethral resection of bladder tumor in non-muscle invasive bladder cancer. Urol Ann. 2014; 6(4):305-8. PMC: 4216535. DOI: 10.4103/0974-7796.140990. View

10.

Richterstetter M, Wullich B, Amann K, Haeberle L, Engehausen D, Goebell P . The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU Int. 2012; 110(2 Pt 2):E76-9. DOI: 10.1111/j.1464-410X.2011.10904.x. View

11.

Lodde M, Mayr R, Martini T, Comploj E, Palermo S, Trenti E . Positive urine cytology and carcinoma in situ prior to second transurethral resection of the bladder correlate with positive second resection histology and the need for subsequent cystectomy. World J Urol. 2012; 30(6):841-6. DOI: 10.1007/s00345-012-0975-1. View

12.

Ojerholm E, Smith A, Hwang W, Baumann B, Tucker K, Lerner S . Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer. 2016; 123(5):794-801. PMC: 5319875. DOI: 10.1002/cncr.30422. View

13.

Tazeh N, Canter D, Damodaran S, Rushmer T, Richards K, Abel E . Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences. Bladder Cancer. 2017; 3(2):89-94. PMC: 5409044. DOI: 10.3233/BLC-160085. View

14.

Liu W, Qi L, Zu X, Li Y, He W, Tong S . A preoperative marker panel for the prediction of residual tumor and the decision making for repeat transurethral resection. Urol Oncol. 2015; 33(4):165.e9-14. DOI: 10.1016/j.urolonc.2015.01.006. View

15.

Takaoka E, Matsui Y, Inoue T, Miyazaki J, Nakashima M, Kimura T . Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era. Jpn J Clin Oncol. 2013; 43(4):404-9. DOI: 10.1093/jjco/hyt016. View

16.

Lucca I, Jichlinski P, Shariat S, Roupret M, Rieken M, Kluth L . The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. Eur Urol Focus. 2017; 2(1):79-85. DOI: 10.1016/j.euf.2015.03.001. View

17.

Del Zingaro M, Bruno R, Nunzi E, Porena M, Mearini L . First and second transurethral resections in intermediate-high risk bladder cancer: impact of the surgeon's volume on the recurrence and progression of primary bladder cancer. Minerva Urol Nefrol. 2015; 68(2):194-203. View

18.

Mbeutcha A, Shariat S, Rieken M, Rink M, Xylinas E, Seitz C . Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urol Oncol. 2016; 34(11):483.e17-483.e24. DOI: 10.1016/j.urolonc.2016.05.013. View

19.

Kluth L, Xylinas E, Crivelli J, Passoni N, Comploj E, Pycha A . Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. J Urol. 2013; 190(2):480-6. DOI: 10.1016/j.juro.2013.01.089. View

20.

Hartinger J, Haussermann R, Olbert P, Hofmann R, Hegele A . [Predictors for presence of residual tumor in follow-up transurethral resection of bladder tumors: single center results]. Urologe A. 2013; 52(4):557-61. DOI: 10.1007/s00120-012-3109-x. View